File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.12809/hkmj133804
- Scopus: eid_2-s2.0-84878864745
- PMID: 23568936
- WOS: WOS:000320295600008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer
Title | Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer |
---|---|
Authors | |
Keywords | Prostate neoplasms Drug therapy Androgen antagonists Survival |
Issue Date | 2013 |
Citation | Hong Kong Medical Journal, 2013, v. 19, n. 3, p. 237-241 How to Cite? |
Abstract | Objective To determine the effectiveness and toxicity of docetaxel for Chinese patients with castrate-resistant prostate cancer in a local Hong Kong hospital. Design Case series. Setting A tertiary cancer centre in Hong Kong. Patients In all, 39 castrate-resistant prostate cancer patients were treated with 3-weekly docetaxel at 75 mg/m 2 and prednisolone 10 mg daily between January 2006 and December 2011 in Queen Elizabeth Hospital. Main outcome measures Prostate-specific antigen control rate, pain control rate, progression-free survival, overall survival, and complication rates. Results The prostate-specific antigen response rate was 36%, and 27 (69%) of the patients had improved pain control after chemotherapy. The median progression-free survival, cancer-specific survival, and overall survival was 7.8 (95% confidence interval, 4.9-10.8) months, 13.0 (95% confidence interval, 9.6-16.3) months, and 12.2 (95% confidence interval, 9.3-15.1) months, respectively. The grade 3 anaemia and thrombocytopenia rates were 5%, and the neutropenic fever rate was 8%. Conclusions Chemotherapy with docetaxel at a dose of 75 mg/m 2 given once every 3 weeks together with daily prednisolone is well tolerated in Chinese and can offer good symptom palliation in suitable patients with castrate-resistant prostate cancer. |
Persistent Identifier | http://hdl.handle.net/10722/251623 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cheun, F. Y. | - |
dc.contributor.author | Leung, K. C. | - |
dc.contributor.author | Ngan, Roger K C | - |
dc.date.accessioned | 2018-03-08T05:00:30Z | - |
dc.date.available | 2018-03-08T05:00:30Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | Hong Kong Medical Journal, 2013, v. 19, n. 3, p. 237-241 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/251623 | - |
dc.description.abstract | Objective To determine the effectiveness and toxicity of docetaxel for Chinese patients with castrate-resistant prostate cancer in a local Hong Kong hospital. Design Case series. Setting A tertiary cancer centre in Hong Kong. Patients In all, 39 castrate-resistant prostate cancer patients were treated with 3-weekly docetaxel at 75 mg/m 2 and prednisolone 10 mg daily between January 2006 and December 2011 in Queen Elizabeth Hospital. Main outcome measures Prostate-specific antigen control rate, pain control rate, progression-free survival, overall survival, and complication rates. Results The prostate-specific antigen response rate was 36%, and 27 (69%) of the patients had improved pain control after chemotherapy. The median progression-free survival, cancer-specific survival, and overall survival was 7.8 (95% confidence interval, 4.9-10.8) months, 13.0 (95% confidence interval, 9.6-16.3) months, and 12.2 (95% confidence interval, 9.3-15.1) months, respectively. The grade 3 anaemia and thrombocytopenia rates were 5%, and the neutropenic fever rate was 8%. Conclusions Chemotherapy with docetaxel at a dose of 75 mg/m 2 given once every 3 weeks together with daily prednisolone is well tolerated in Chinese and can offer good symptom palliation in suitable patients with castrate-resistant prostate cancer. | - |
dc.language | eng | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.subject | Prostate neoplasms | - |
dc.subject | Drug therapy | - |
dc.subject | Androgen antagonists | - |
dc.subject | Survival | - |
dc.title | Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.12809/hkmj133804 | - |
dc.identifier.pmid | 23568936 | - |
dc.identifier.scopus | eid_2-s2.0-84878864745 | - |
dc.identifier.volume | 19 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 237 | - |
dc.identifier.epage | 241 | - |
dc.identifier.isi | WOS:000320295600008 | - |
dc.identifier.issnl | 1024-2708 | - |